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ABSTRACT
Objective The inﬂammatory cytokine, tumour necrosis
factor α (TNF-α), exerts deleterious cardiovascular
effects. We wished to determine the effects of TNF-α
antagonism on endothelial function and platelet
activation in patients with acute myocardial infarction.
Design and setting and patients A double-blind,
parallel group, randomised controlled trial performed in
a tertiary referral cardiac centre. 26 patients presenting
with acute myocardial infarction randomised to receive
an intravenous infusion of etanercept (10 mg) or saline
placebo.
Main outcome measures Leucocyte count, plasma
cytokine concentrations, ﬂow cytometric measures of
platelet activation and peripheral vasomotor and
ﬁbrinolytic function were determined before and 24 h
after study intervention.
Results Consistent with effective conjugation of
circulating TNF-α, plasma TNF-α concentrations
increased in all patients following etanercept
(254±15 vs 0.12±0.02 pg/ml; p<0.0001), but not
saline infusion. Etanercept treatment reduced neutrophil
(7.4±0.6 vs 8.8±0.6×109 cells/l; p=0.03) and plasma
interleukin-6 concentrations (5.8±2.0 vs 10.6±4.0 pg/ml;
p=0.012) at 24 h but increased platelet–monocyte
aggregation (30±5 vs 20±3%; p=0.02).
Vasodilatation in response to substance P, acetylcholine
and sodium nitroprusside, and acute tissue plasminogen
activator release were unaffected by either treatment
(p>0.1 for all).
Conclusions Following acute myocardial infarction,
etanercept reduces systemic inﬂammation but increases
platelet activation without affecting peripheral vasomotor
or ﬁbrinolytic function. We conclude that TNF-α
antagonism is unlikely to be a beneﬁcial therapeutic
strategy in patients with acute myocardial infarction.
INTRODUCTION
The relationship between inﬂammatory disorders
and atherosclerosis has been recognised for over a
century, and there now exists clear evidence to
support the concept that immune responses are
critical in the initiation, progression and destabilisa-
tion of atherosclerosis. T lymphocytes and mono-
cytes are present within stable and unstable
atherosclerotic plaques, and act to mediate
both atherogenesis and plaque destabilisation.1
The inﬂammatory nature of atherosclerosis is
exempliﬁed by the high incidence of cardiovascular
disease in patients with chronic inﬂammatory con-
ditions, such as rheumatoid arthritis2 and systemic
lupus erythematosis,3 independent of traditional
cardiovascular risk factors. Similarly, acute inﬂam-
mation, such as that occurring in the context of
infections of the respiratory and urinary tract, is
temporally associated with an increased incidence
of adverse cardiovascular events such as myocardial
infarction and stroke.4 Elevated concentrations of
inﬂammatory mediators predict the occurrence of
adverse cardiovascular events, even in apparently
healthy low risk individuals without overt cardio-
vascular disease.5 Despite the longstanding recogni-
tion of the importance of inﬂammation in the
development of atherosclerosis and the precipita-
tion of thrombotic events, anti-inﬂammatory
therapy for the treatment of atherosclerosis has
received little attention. However, targeted anti-
inﬂammatory therapy is a highly attractive concept,
particularly for the treatment of acute vascular
inﬂammation, as this is a universal component of
the development of acute coronary syndromes.
Tumour necrosis factor α (TNF-α) is a
pro-inﬂammatory cytokine secreted by activated
macrophages and T cells, and is instrumental in the
mediation of vascular inﬂammation. TNF-α recep-
tors are expressed on all critical cellular effectors of
atherogenesis, namely, vascular endothelial and
smooth muscle cells, and activated leucocytes such
as T lymphocytes and macrophages.6 TNF-α pro-
duction is deleterious to vascular homeostasis
through the induction of endothelial surface adhe-
sion molecule expression mediating platelet–leuco-
cyte interactions, cellular aggregation and thrombus
formation.7 TNF-α production is increased in
unstable atherosclerotic plaques8 and is detectable
in increased concentrations in patients with acute
myocardial infarction (AMI).9 Furthermore, plasma
TNF-α concentrations are predictive of death and
recurrent ischaemic events following AMI.10 We
have previously demonstrated that TNF-α mediates
vascular inﬂammation with potentially beneﬁcial
pro-ﬁbrinolytic effects; however, it is associated
with adverse inhibitory effects on endothelium-
dependent vasodilatation.11 Consistent with these
deleterious effects, antagonism of the TNF-α recep-
tor has been demonstrated to improve
endothelium-dependent vasodilatation in a variety
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of clinical settings such as congestive cardiac failure,12 acute sys-
temic vasculitis13 and rheumatoid arthritis.14 The positive vascu-
lar effects of TNF-α antagonism may therefore be beneﬁcial in
the management of acute coronary syndromes, which are
strongly associated with endothelial dysfunction. We therefore
studied the effects of the TNF-α receptor antagonist, etanercept,
on peripheral vasomotor and ﬁbrinolytic function, and platelet
activation in patients presenting with recent AMI.
METHODS
Subjects
The study was performed with the approval of the local
research ethics committee in accordance with the Declaration of
Helsinki and with the written informed consent of all partici-
pants. Inclusion criteria were a typical history of myocardial
ischaemia lasting more than 20 min within 24 h of hospitalisa-
tion with ischaemic electrocardiographic changes and an ele-
vated troponin-I concentration (>0.2 mg/l). Patients were
excluded in the event of signiﬁcant comorbidity, including active
systemic inﬂammatory disorders, insulin-dependent diabetes
mellitus and the use of anti-inﬂammatory drugs other than
aspirin. Given the immunosuppressive effects of etanercept,
exclusion criteria also included any history of recent or recur-
rent infection, tuberculosis or any opportunistic infection within
the previous 6 months.
Study design
In a randomised, double-blind, parallel group design, patients
were evaluated on two occasions: before and 24 h after intra-
venous administration of the TNF-α antagonist, etanercept
(10 mg), or saline placebo. A single subcutaneous 25 mg dose of
etanercept improves endothelium-dependent vasodilatation
within 6 h of administration in patients with heart failure.12 In
order to achieve a rapid onset of action, we elected to use the
intravenous route, and single intravenous doses of up to 10 mg/m2
have been used safely in patients with heart failure.15
Subcutaneous etanercept has 23% bioavailability and achieves
peak plasma concentrations of 0.43 mg/ml at 66 h.16 In contrast, a
single intravenous dose of 10 mg etanercept achieves a maximum
concentration of 2.32 mg/ml at 50 min.16 Given a plasma half-life
of approximately 70 h,16 we judged that 24 h would be an appro-
priate time point to capture any potential beneﬁcial cardiovascular
effects of intravenous etanercept. Randomisation was performed
by a computer generated sequence to ensure concealment of treat-
ment allocation and following minimisation for age, sex, time to
randomisation, peak troponin, serum cholesterol and cardiovascu-
lar risk factors including diabetes mellitus, hypertension and
smoking.17 Study procedures were all completed prior to invasive
angiography or percutaneous coronary intervention.
Venous sampling and cytokine analysis
Patients abstained from food and caffeine containing drinks for
4 h, and 24 h from ingestion of alcohol prior to phlebotomy.
Blood samples were obtained through a 17-gauge cannula with
careful attention to ensure smooth extraction of blood to
avoid artefactual platelet activation ex vivo, and anticoagulated
with D-phenylalanyl-L-propyl-L-arginine chloromethyl-ketone
(PPACK). During vasomotor assessments, venous blood was
withdrawn simultaneously from each arm and collected into
tubes containing acidiﬁed buffered citrate (for t-PA assays), triso-
dium citrate (for plasminogen activator inhibitor type 1 (PAI-1)
assays) and potassium EDTA (for cytokine assays). Citrate and
acidiﬁed buffered citrate samples were centrifuged at 2000 g for
30 min at 4°C and EDTA samples at 1000 g for 10 min at 20°C.
Platelet-free plasma was decanted and stored at -80°C before
assay. Plasma TNF-α and IL-6 concentrations were determined
as described previously18 using ELISA (Quantikine human TNF
and IL-6 immunoassays, R&D Systems; and Dako A/S, respect-
ively) and ﬁbrinolytic activities using a photometric method
(Coatest t-PA and PAI-1, Chomogenix AB). Haematocrit and
white cell count were determined using an automated Coulter
counter (Beckman-Coulter).
Vasomotor assessment
Assessment of vasomotor function in response to intra-arterial
vasodilators was performed as described previously.19 Brieﬂy,
studies were performed in a quiet, temperature-controlled envir-
onment with the patient in the supine position throughout.
Venous 17-gauge cannulae were inserted into each forearm for
blood sampling and a 27-standard wire gauge steel needle
placed in the brachial artery of the non-dominant forearm for
vasodilator infusions. A baseline 30 min intra-arterial infusion
of saline was followed by intra-arterial infusion of substance P at
2, 4 and 8 pmol/min; then acetylcholine at 5, 10 and 20 mg/
min; and ﬁnally sodium nitroprusside at 2, 4 and 8 μg/min,
infused for 10 min at each dose with each agonist separated by a
20 min saline infusion. Forearm blood ﬂow was measured in
both arms by venous occlusion plethysmography with the use of
mercury-in-silastic strain gauges. Heart rate and blood pressure
in the non-infused arm were monitored at intervals throughout
with the use of a semiautomated, non-invasive oscillometric
sphygmomanometer.
Immunostaining and ﬂow cytometry
All reagents were obtained from AbD Serotec (Oxford, UK)
unless otherwise stated. The following antibodies were used:
IgG1-FITC, CD14-PE, CD42a-FITC, IgG2a-PE, CD62P-PE,
IgG1-PE (eBioscience Ltd. UK) and CD14-RPE and IgG1-RPE
(DakoCytomation, Denmark). All antibodies were diluted 1:20
with ﬂow buffer. FACS-Lyse was obtained from Becton-
Dickinson (Cowley, UK). Blood anticoagulated with PPACK was
labelled with the appropriate antibodies exactly 5 min from col-
lection and incubated in the dark for 20 min at room tempera-
ture. Immunolabelling was performed on whole blood to avoid
artefactual platelet activation caused by puriﬁcation procedures.
Samples were then ﬁxed and run through a FACSCalibur
(Becton-Dickinson) ﬂow cytometer within 2 h of ﬁxing using an
established ﬂow protocol.20 For determination of PMA a total
of 3000 events were collected in the CD14 monocyte gate. For
platelet expression of P-selectin 7500 events were collected in
the platelet gate.
Data and statistical analysis
Cytometric data analysis was performed with FlowJo V.7.2.5
(Flow Cytometry Analysis Software). Plethysmographic data and
net t-PA release were determined as described previously,19 21 as
the product of the infused forearm plasma ﬂow (based on the
mean haematocrit and the infused FBF) and the concentration
difference between the infused ([t-PA] inf) and non-infused
([t-PA] non-inf) arms: estimated net t-PA release=FBF×(1−Hct)×
([tPA]inf−[tPA]non-inf ). Continuous variables are reported as
means±SEM. Analysis of variance with repeated measures and a
two-tailed Student t test were performed as appropriate with
the use of GraphPad Prism software. The primary outcome
measure was PMA. On the basis of previous work examining
the effect of clopidogrel on PMA22 we estimated that a 5%
absolute change in PMA would be of clinical signiﬁcance and
that at least 12 paired samples would provide an 80% power to
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detect a 10% absolute difference in PMA from baseline at a sig-
niﬁcance level of 5%.
RESULTS
26 patients hospitalised with type 1 acute non-STelevation myo-
cardial infarction were recruited into the study. Patients were
well matched with respect to all relevant baseline characteristics
(table 1). No additional medical therapy was instituted during
the study period. No serious adverse events occurred during the
study.
Inﬂammatory response and cytokine analyses
Consistent with effective conjugation of circulating TNF-α,
plasma TNF-α concentrations increased in all patients following
etanercept infusion (254±15 vs 0.12±0.02 pg/ml; p<0.0001).
At 24 h, treatment with etanercept was associated with a
reduced neutrophil count (8.8±0.6 vs 7.4±0.5 cells 109/l;
p=0.02), and a rise in the lymphocyte count (2.3±0.2 vs 2.7
±0.26; p=0.001), with a reduction in the neutrophil to
lymphocyte ratio following etanercept compared with placebo
(−1.3±0.4 vs 0.17±0.2; p=0.001). Plasma interleukin-6 con-
centrations were similarly reduced (10.6±4.0 vs 5.8±2.0 pg/ml;
p=0.01). No signiﬁcant differences were observed at 24 h com-
pared with baseline in those patients randomised to placebo
(p>0.05 for all; table 2).
Platelet activation
PMA and platelet P-selectin expression were similar between the
groups at baseline. Following etanercept infusion, there was a
50% relative increase in PMA (30±5 vs 20±3%; p=0.02) com-
pared with baseline. PMA was however unaffected by saline
placebo infusion (28±5 vs 33±6%; p=0.23). Platelet P-selectin
expression was not affected by either treatment (p>0.05 for
both; table 2).
Vasomotor response
Of the 26 patients enrolled, 15 underwent vascular assessment
(eight randomised to receive etanercept). Heart rate and sys-
temic blood pressure were similar in both groups and were
unaffected by either treatment (data not shown). Baseline
forearm blood ﬂow in the non-infused arm was similar and was
unaffected by either treatment. There was a dose-dependent
increase in forearm blood ﬂow with all intra-arterial vasodila-
tors: substance P, acetylcholine and sodium nitroprusside
(p<0.001). However, there were no differences in the dose–
response curves between etanercept and placebo (p>0.1 for all;
ﬁgure 1).
Fibrinolytic response
Plasma t-PA activity concentrations were similar between groups
at baseline and were unaffected by saline placebo (p=1.0).
Following etanercept, plasma t-PA activity concentrations were









Age, years 62±2 63±3 61±4 0.63
Male, n (%) 19 (73) 10 (77) 9 (69) 0.66
Time to randomisation (h)* 67.9±7.8 70.5±8.1 64.7±14.5 0.32
Peak troponin (ng/ml) 8.3±2.3 8.9±3.8 7.7±2.5 0.79
Cholesterol (mg/l) 5.5±0.3 5.5±0.3 5.5±0.4 0.98
Blood pressure (mm Hg) 135/75±5/3 137/79±6/4 132/73±7/3 >0.3
Current smoker, n (%) 6 (23) 4 (31) 2 (15) 0.87
Diabetes mellitus, n (%) 2 (8) 2 (15) 0 (0) 0.14
Prior AMI, n (%) 9 (35) 5 (40) 4 (35) 0.68
Hypertension, n (%) 9 (35) 5 (38) 4 (31) 0.68
Hypercholesterolaemia, n (%) 8 (31) 5 (38) 3 (23) 0.40
Aspirin, n (%) 26 (100) 13 (100) 13 (100) 1.0
Clopidogrel, n (%) 26 (100) 13 (100) 13 (100) 1.0
LMWH, n (%) 22 (85) 11 (85) 11 (85) 1.0
ACE inhibitor, n (%) 10 (42) 7 (54) 4 (31) 0.43
β Blocker, n (%) 21 (88) 9 (69) 12 (92) 0.14
Statin, n (%) 22 (85) 10 (77) 12 (92) 0.28
Ca channel antagonist, n (%) 2 (8) 0 (0) 2 (15) 0.14
Data expressed are means±SEM or the number of cases and percentage of the group.
Groups are compared by a χ2 test or student t test for categorical and continuous
data, respectively.
*Time to randomisation describes the interval between the onset of ischaemic
symptoms and the first study blood sample.
AMI, acute myocardial infarction; LMWH, low molecular weight heparin.
Table 2 Inflammatory response, indices of platelet activation and fibrinolytic function
Placebo Etanercept
Pre Post p Value Pre Post p Value
Cellular response
Neutrophils×109 cells/l 7.7±0.6 7.2±0.5 0.16 8.8±0.5 7.4±0.5* 0.02
Lymphocytes×109 cells/l 2.0±0.1 1.9±0.1 0.19 2.3±0.2 2.7±0.26* 0.001
Monocytes×109 cells/l 0.7±0.1 0.6±0.1 0.29 0.7±0.1 0.7±0.1 0.16
Cytokines
Interleukin-6 (pg/ml) 7.5±1.9 5.0±1.3 0.13 10.6±4.0 5.8±2.0* 0.01
TNF-α (pg/ml) <0.1 <0.1 - 0.12±0.02 254±14* <0.0001
Platelet activation
Platelet monocyte aggregates (%) 27.7±4.9 33±5.8 0.23 20.3±2.9 30.2±5.2* 0.02
Platelet surface P-selectin+ (%) 6.7±0.5 6.5±0.7 0.76 6.2±1.3 5.0±0.7 0.15
Fibrinolytic function
t-PA activity (IU/ml) 0.45±0.14 0.45±0.10 1.00 0.77±0.09 0.52±0.09* 0.001
PAI-1 activity (IU/ml) 1.5 (0.8–2.7) 0.9 (0.6–2.4) 0.13 0.5 (0.4–0.9) 1.1 (0.3–1.5) 0.17
Data are expressed as the mean±SE or median (IQR) where appropriate. Statistical analyses compare 24 h with baseline using a paired t test or Mann–Whitney where appropriate.
*p<0.05.
PAI-1, plasminogen activator inhibitor type 1; TNF-α, tumour necrosis factor α.
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reduced at 24 h (0.8±0.1 vs 0.5±0.1 IU/ml; p=0.001).
Compared with the non-infused arm, substance P caused dose-
dependent increases in plasma t-PA activity (ANOVA: p=0.001).
However, dose–response curves were similar at 24 h and were
unaffected by either treatment (p>0.1 for all; table 2; ﬁgure 2).
Plasma PAI-1 antigen concentrations were similar between the
groups at baseline and did not differ following either treatment
(p>0.1).
DISCUSSION
This is the ﬁrst study to evaluate the effect of TNF-α antagon-
ism in patients with AMI. We demonstrate that although provid-
ing a modest anti-inﬂammatory effect, treatment with
etanercept was not associated with any improvement in periph-
eral vasomotor or ﬁbrinolytic function. Of potential concern,
we identiﬁed an increase in platelet monocytes aggregation sig-
nalling a potentially adverse pro-thrombotic effect. We conclude
that TNF-α antagonism does not appear to provide beneﬁcial
cardiovascular effects in patients with AMI and is unlikely to be
a beneﬁcial novel therapy in this setting.
Etanercept is a dimeric fusion protein that consists of the
extracellular ligand-binding domain of the human TNF recep-
tor, linked to the Fc portion of human IgG1. Etanercept inacti-
vates circulating TNF-α by binding to it, thereby preventing
activation of endogenous TNF-α receptors. Consistent with pre-
vious reports,23 we observed a dramatic increase in plasma
TNF-α concentrations following treatment with etanercept.
Etanercept paradoxically increases the immunoreactivity and sta-
bility of circulating TNF-α, probably as a consequence of its
dimeric structure, which can cause an increase in the relative
quantities of circulating homotrimeric, as opposed to mono-
meric or dimeric, TNF-α.24 This paradoxical effect of TNF-α
antagonism can lead to an effective increase in TNF-α mediated
cytotoxicity, and this effect appears to be particularly pro-
nounced where there is a marked molar excess of TNF-α rela-
tive to etanercept. Although we did not observe any direct
vascular effects associated with the increase in plasma TNF-α
concentrations, we did observe a 50% relative increase in PMA,
a measure of platelet activation. We have previously observed an
approximate 20% fall in PMA following treatment with clopi-
dogrel,22 suggesting that the increase associated with treatment
with etanercept is clinically relevant. These ﬁndings are consist-
ent with previous in vitro studies showing that TNF-α can cause
an increase in platelet aggregation in patients with heart failure,
probably through activation of the arachadonic acid
pathway.25 26 Enhanced platelet activation through this mechan-
ism may in part explain the thrombotic tendency associated
with disorders characterised by high plasma concentrations of
TNF-α.7 However, we did not detect a difference in P-selectin
expression, an alternate measure of platelet activation. P-selectin
expression is generally very transient with low levels of expres-
sion, making this a less reliable in vivo marker of platelet activa-
tion.27 Although this may explain our discrepant ﬁndings, we
would suggest caution in interpreting the signiﬁcance of our
ﬁndings with PMA given that this was a single measure of plate-
let activation.
The recognition that heart failure is characterised by high
plasma concentrations of TNF-α has stimulated intensive
research of TNF-α antagonism in these patients. Interestingly,
although it has been established that antagonism of TNF-α in
the setting of congestive heart failure can ameliorate endothelial
dysfunction,12 and improve left ventricular systolic dysfunc-
tion,28 several large clinical trials of TNF-α antagonists in
patients with congestive heart failure have failed to demonstrate
any clinical beneﬁts associated with this form of treatment.29
Figure 1 Peripheral vasomotor assessment. Forearm blood ﬂow in response to incremental doses of sodium nitroprusside, substance P and
acetylcholine in patients with acute myocardial infarction 24 h following etanercept compared with placebo. Forearm blood ﬂow increases in
response to vasoactive infusion (ANOVA<0.0001 for all); however, there was no difference between treatments (ANOVA≥0.2; ≥0.7 for interaction
for all) or at 24 h compared with baseline (ANOVA>0.1).
Figure 2 Net t-PA activity in response to infusion of substance P.
Net t-PA is calculated as the difference between the infused and
non-infused arm corrected for haematocrit. Net t-PA activity increased
in response to t-PA infusion (ANOVA<0.01); however, there were no
differences between treatments (ANOVA>0.05 for all) or at 24 h
compared with baseline (ANOVA>0.1).
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Furthermore, there is concern over the safety of TNF-α antag-
onism in these patients, as these trials suggest that there may be
an increased risk of the development of worsening heart failure
in those patients receiving higher doses of TNF-α antagonists.30
The present study suggests that increased platelet activation may
in part explain these observations, as any beneﬁcial endothelial
effects associated with etanercept may be offset by an increase
in thrombogenicity. Patients with coronary artery disease gener-
ally have lower plasma concentrations of TNF-α than patients
who have progressed to develop heart failure, limiting extrapo-
lation between these two patient populations.
We have previously demonstrated that intra-arterial TNF-α
causes intense local vascular inﬂammation and a profound
depression of endothelium-dependent vasodilatation, associated
with a compensatory increase in acute t-PA release.31 We there-
fore expected that antagonism of TNF-α would ameliorate vas-
cular inﬂammation, and lead to an improvement in vasomotor
function commensurate with a fall in plasma t-PA concentra-
tions. Consistent with this hypothesis, we found that basal t-PA
activity concentrations were diminished following etanercept.
We have previously hypothesised that t-PA concentrations are
increased in response to vascular inﬂammation as a compensa-
tory mechanism.31 The reduction in basal t-PA activity following
etanercept may therefore reﬂect a fall in basal t-PA release
through amelioration of the systemic inﬂammatory response
associated with AMI. However, neither PAI-1 activity nor net
t-PA release in response to substance P were affected by etaner-
cept infusion, suggesting that the magnitude of this effect was
modest. Furthermore, we saw no effect on vasomotor function.
We suggest that the lack of effect on the vasomotor response
may have been due to the relatively low plasma concentrations
of TNF-α in this cohort of patients. Although concentrations
are increased in patients with AMI,8 9 patients in the present
study had low plasma TNF-α concentrations. The reason for
this is unclear; however, it may be explained by the timing of
patient recruitment into the study (on average 3 days following
presentation) as TNF-α plasma concentrations are maximal
within the ﬁrst 24 h following AMI, falling off markedly there-
after, particularly in the absence of heart failure.32 Selection of
patients with relatively higher plasma concentrations of TNF-α
may have increased the likelihood of observing improvements in
vascular function.
STUDY LIMITATIONS
Although appropriately powered for platelet monocyte aggrega-
tion, confounding factors such as those related to pharmacoki-
netic and pharmacodynamic variation between subjects and the
effects of concurrent medical therapy are challenging to stand-
ardise. To corroborate the observed increase in PMA associated
with etanercept, further measures of platelet function such as
platelet aggregation would be useful.
We cannot exclude the possibility that more rapid treatment
(within the ﬁrst 24 h) and higher doses of etanercept may have
produced different results. However, the marked increase in cir-
culating TNF-α, commensurate with a reduction in systemic
inﬂammation following administration of etanercept, gives us
reassurance that we exerted a meaningful biological effect, and
that the absence of any alteration in vascular function following
treatment was not as a result of a type-2 error.
CONCLUSIONS
The administration of a single dose of etanercept following AMI
provides a modest anti-inﬂammatory effect associated with a
mild reduction in basal plasma t-PA activity. However, this does
not translate into improvements in peripheral vasomotor func-
tion or acute t-PA release. Of concern, etanercept potentiates
platelet–monocyte aggregation, suggesting an adverse effect of
TNF-α antagonism in patients with acute coronary syndromes
through enhanced platelet activation. Further research is
required to explore the effects of etanercept on platelet activa-
tion and function as such effects may in part explain the pos-
sible deleterious effects observed in clinical trials of TNF-α
antagonism in other cardiovascular disorders.
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